Related Experiment Video
Updated: Sep 11, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations
Julian Behn1,2, R N V Krishna Deepak1,3, Jiancheng Hu4,5
1Bioinformatics Institute (BII), Agency for Science, Technology and Research (A⁎STAR), Singapore 138671, Singapore.
Abstract:
Hyperactivation caused by mutations in the Epidermal Growth Factor Receptor (EGFR) kinase domain is implicated in various diseases, including cancer. However, the structural mechanisms underlying overactivation in many EGFR mutations remain poorly understood, and exploring these mechanisms through conventional experiments or in silico simulations is often labor- and cost-intensive. Here, we establish a Molecular Dynamics (MD) protocol capable of rapidly revealing EGFR mutant modes of action using multiple short simulations. We first simulated wild-type EGFR and the well-studied oncogenic mutations L858R and T790M/L858R under different simulation conditions, to derive a protocol which could recapitulate their experimentally established behavior. We then applied this protocol to three rare EGFR mutations: S768I, S768N, and D761N. Experimental studies have suggested that S768I and D761N are oncogenic, whereas S768N is likely a neutral mutation that does not significantly alter EGFR activity. Our simulation results were consistent with these functional indications and provided the corresponding molecular bases - S768I and S768N affect the orientation and stability of the catalytically important αC-helix, while D761N introduces a new hydrogen bonding network between the αC-helix and activation loop. Collectively, the protocol presented here provides a robust and rapid framework for characterizing EGFR mutation mechanisms and is readily adaptable to novel or uncharacterized variants.
Insights
A new Molecular Dynamics protocol rapidly reveals how Epidermal Growth Factor Receptor (EGFR) mutations cause disease. This method efficiently characterizes novel EGFR variants, aiding cancer research.
Area of Science:
- Biochemistry
- Molecular Biology
- Computational Biology
Background:
- Mutations in Epidermal Growth Factor Receptor (EGFR) kinase domain cause hyperactivation, linked to various diseases like cancer.
- Understanding the structural mechanisms of EGFR overactivation is crucial but often hindered by labor- and cost-intensive experimental and computational methods.
Purpose of the Study:
- To establish a rapid and robust Molecular Dynamics (MD) protocol for characterizing the mechanisms of EGFR mutations.
- To apply this protocol to rare EGFR mutations and elucidate their molecular bases.
Main Methods:
- Developed and validated a Molecular Dynamics (MD) protocol using multiple short simulations.
- Simulated wild-type EGFR and known oncogenic mutations (L858R, T790M/L858R) to refine the protocol.
- Applied the validated protocol to rare EGFR mutations (S768I, S768N, D761N).
Main Results:
- The MD protocol successfully recapitulated experimentally established behaviors of known EGFR mutations.
- Simulations provided molecular insights into the oncogenic potential of S768I and D761N mutations.
- Identified specific effects of S768I/S768N on the αC-helix and D761N on hydrogen bonding networks.
Conclusions:
- The developed MD protocol offers a rapid and robust framework for characterizing EGFR mutation mechanisms.
- This approach is adaptable for analyzing novel or uncharacterized EGFR variants.
- The findings provide molecular-level understanding of rare EGFR mutations, potentially aiding therapeutic strategies.
More Related Videos
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016